glp-1 receptor agonists are contraindicated in Frontiers contraindications to glp 1 ๐ฐ๏ธ60-second
Description
Structure Therapeutics has already disclosed an oral small-molecule amylin program (ACCG-2671, ACCG-3535) intended for fixed-dose combination with GLP-1RAs, and is working on small-molecule agonists at GIP, glucagon and apelin receptors
Dis Model Mech
Effect of glucagon on food intake and body weight in man
doi: 10.1517/14728222.2011.600691 126 DoughertyJAGuirguisEThornbyKA
The FDA based its decision on outcomes from the 2-year SUSTAIN 6 trial where Ozempic reduced the risk of MACE by 26%
